
    
      In this trial, approximately 50 patients will receive the study drug, RAD001 in combination
      with bevacizumab (Avastin)chemotherapy. RAD001 will be taken orally once daily and
      bevacizumab will be administered intravenously once every 14 days. In addition to study
      treatment, a few blood samples and a sample of the patients tumor from a previous surgery if
      available will be collected for research.
    
  